ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

EDAP EDAP TMS SA

5.1208
0.1358 (2.72%)
Last Updated: 17:32:19
Delayed by 15 minutes
Share Name Share Symbol Market Type
EDAP TMS SA NASDAQ:EDAP NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.1358 2.72% 5.1208 5.12 5.16 5.20 5.00 5.108 1,690 17:32:19

EDAP to Present at Rodman & Renshaw Annual Global Investment Conference

09/09/2010 2:25pm

GlobeNewswire Inc.


EDAP TMS (NASDAQ:EDAP)
Historical Stock Chart


From Jul 2019 to Jul 2024

Click Here for more EDAP TMS Charts.

EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic ultrasound, today announced that Marc Oczachowski, Chief Executive Officer, and Eric Soyer, Chief Financial Officer, are scheduled to present at the Rodman & Renshaw Annual Global Investment Conference that will be held in New York City from September 12 to 15, 2010.

Event: Rodman & Renshaw Annual Global Investment Conference
Presentation Date:  Monday, September 13, 2010
Presentation Time: 4:55 pm ET – 5:20 pm ET

A live Web cast of the presentation will be available on EDAP's Web site at http://investor.edap-tms.com/events.cfm. Replay of the Web cast will be available for 30 days after the date of the presentation.

About EDAP TMS SA

EDAP TMS SA develops and markets Ablatherm, the most advanced and clinically proven choice for high-intensity focused ultrasound (HIFU) treatment of localized prostate cancer. HIFU treatment is shown to be a minimally invasive and effective treatment option with a low occurrence of side effects. Ablatherm-HIFU is generally recommended for patients with localized prostate cancer (stages T1-T2) who are not candidates for surgery or who prefer an alternative option, or for patients who failed radiotherapy treatment. Approved in Europe as a treatment for prostate cancer, Ablatherm-HIFU (High Intensity Focused Ultrasound) is currently undergoing evaluation in a multicenter U.S. Phase II/III clinical trial under an Investigational Device Exemption granted by the FDA, the ENLIGHT U.S. clinical study. The Company also is developing this technology for the potential treatment of certain other types of tumors. EDAP TMS SA also produces and commercializes medical equipment for treatment of urinary tract stones using extra-corporeal shockwave lithotripsy (ESWL). For more information on the Company, please visit http://www.edap-tms.com, http://www.hifu-planet.com.

CONTACT:  EDAP TMS SA
          Investor Relations/Legal Affairs
          Blandine Confort
          +33 4 72 15 31 72
          bconfort@edap-tms.com

          The Ruth Group
          Investors:
          Stephanie Carrington 
          646-536-7017
          scarrington@theruthgroup.com

1 Year EDAP TMS Chart

1 Year EDAP TMS Chart

1 Month EDAP TMS Chart

1 Month EDAP TMS Chart